Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO MCBS  1000x150

The ESMO-MCBS Scorecards provides a centralised location of cancer medicines that have been scored and published by ESMO.

It includes all cancer medicines approved by the European Medicines Agency (from January 2016) and the US Food and Drug Administration (from January 2020).

ESMO-MCBS Scores
Number of studies
Non-curative setting
5 20
4 104
3 141
2 36
1 21
Curative setting
A 41
C 3
ESMO-MCBS Scores by tumour type
Non-curative setting
Brain Tumours 2
Breast Cancer 34
Central Nervous System Malignancies 1
Endocrine Tumours 20
Gastrointestinal Cancers 59
Genitourinary Cancers 54
Gynaecological Malignancies 32
Head and neck cancer 9
Melanoma 21
RET fusion-positive tumours 1
Refractory NTRK fusion–positive cancers 2
Sarcoma 9
Skin Cancers 6
TMB-H solid tumours 1
Thoracic Malignancies 70
dMMR/MSI-H solid tumours 1
Curative setting
Brain Tumours 0
Breast Cancer 7
Central Nervous System Malignancies 1
Endocrine Tumours 0
Gastrointestinal Cancers 15
Genitourinary Cancers 3
Gynaecological Malignancies 0
Head and neck cancer 0
Melanoma 11
RET fusion-positive tumours 0
Refractory NTRK fusion–positive cancers 0
Sarcoma 2
Skin Cancers 1
TMB-H solid tumours 0
Thoracic Malignancies 4
dMMR/MSI-H solid tumours 0

The ESMO-MCBS Scorecards

The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.

Evaluation form 1  For new approaches to adjuvant therapy or new potentially curative therapies
Evaluation form 2a For therapies that are not likely to be curative with primary endpoint of OS with separate sheets for:
Evaluation form 2b For therapies that are not likely to be curative with primary endpoint PFS with separate sheets for:
Evaluation form 2c  For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies
Evaluation form 3  For single-arm studies in “orphan diseases” and for diseases with “high unmet need” when primary outcome is PFS or ORR.
Quality of Life Checklist To evaluate ESMO-MCBS score adjustments based on quality of life

My watchlist

    Tested Agent(s) Combined Agent(s) Control Arm Treatment Setting Tumour Type Tumour Sub-type Tumour Sub-group Trial Name Ref. Score Scorecard Scorecard
    Tepotinib - Single arm (Phase II) Treatment for patients with NSCLC harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping following prior treatment with immunotherapy and/or platinum-based ChT Thoracic Malignancies Non-small-cell Lung Cancer METex14 skipping VISION
    3

    PRELIMINARY SCORE

    • OS
      6

    ADJUSTMENTS

    FINAL SCORE

    • F1
      3
    Cemiplimab - Platinum based ChT (Crossover allowed) First-line unresectable Thoracic Malignancies Non-small-cell Lung Cancer PD-L1>50% negative EGFR, ALK or ROS1 EMPOWER-Lung 1
    4

    PRELIMINARY SCORE

    • OS
      5

    ADJUSTMENTS

    FINAL SCORE

    • F1
      2
    Cabozantinib - Sunitinib First-line treatment of adult patients with intermediate or poor risk advanced RCC Genitourinary Cancers Renal cell cancer - CABOSUN
    3

    PRELIMINARY SCORE

    • OS
      6

    ADJUSTMENTS

    FINAL SCORE

    • F1
      3
    Dostarlimab - Single arm (Phase I) Treatment of adult patients with dMMR/MSI-H recurrent or advanced endometrial cancer that have progressed on or following prior treatment with a platinum-containing regimen Gynaecological Malignancies Endometrial Cancer dMMR or MSI-H GARNET
    3

    PRELIMINARY SCORE

    • OS
      6

    ADJUSTMENTS

    FINAL SCORE

    • F1
      3
    Nivo/Ipi (nivolumab and ipilimumab) 2 cycles of platinum-based ChT Chemotherapy First line treatment of mNSCLC with no sensitising EGFR mutation or ALK translocation Thoracic Malignancies Non-small-cell Lung Cancer - CheckMate-9LA
    4

    PRELIMINARY SCORE

    • OS
      5

    ADJUSTMENTS

    FINAL SCORE

    • F1
      2
    5-FU/LV (5-fluorouracil + leucovorin) - Lomustine (MeCCNU) + vincristine + 5-FU Patients with Dukes' stage B and C colon cancer Gastrointestinal Cancers Colon Cancer - NSABP C-03
    A

    ADJUSTMENTS

    FINAL SCORE

    • F1
      1
    5-FU (fluorouracil) Folinic acid Observation Patients with surgically resected colon cancer in Dukes' stage C Gastrointestinal Cancers Colon Cancer - -
    A

    ADJUSTMENTS

    FINAL SCORE

    • F1
      1
    5-FU/LV (fluorouracil + leucovorin) - Observation High-risk stage II or stage III colon cancer Gastrointestinal Cancers Colon Cancer - NCCTG 874651
    A

    ADJUSTMENTS

    FINAL SCORE

    • F1
      1
    5-FU (fluorouracil) Folinic acid Surgery alone Patients with resectable Dukes B and C (AJCC/UICC Stage II and Stage III) colon carcinoma Gastrointestinal Cancers Colon Cancer - GIVIO-SITAC 01
    A

    ADJUSTMENTS

    FINAL SCORE

    • F1
      1
    5-FU/LV (fluorouracil + leucovorin) or 5-FU/LEV (fluorouracil + levamisole) - Surgery alone (Meta-analysis) Patients with stage II and III colon cancer (ITT and age stratified including >70 years) Gastrointestinal Cancers Colon Cancer - -
    A

    ADJUSTMENTS

    FINAL SCORE

    • F1
      1

    This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

    For more detailed information on the cookies we use, please check our Privacy Policy.

    Customise settings
    • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.